Poor clinical outcomes and immunoevasive contexture in CD161CD8 T cells barren human pancreatic cancerQiangda Chen, Hanlin Yin, Zhenlai Jiang, Taochen He, Yuqi Xie, Weilin Mao, Jiande Han, Siyao Liu, Wenhui Lou, Wenchuan Wu, Joseph R Habib, Jun Yu, Liang Liu, Ning Pu
26 March 2024
Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysisJimmy S Patel, Yena Woo, Amber Draper, Caroline S Jansen, Jennifer W Carlisle, Pasquale F Innominato, Francis A Lévi, Layla Dhabaan, Viraj A Master, Mehmet A Bilen, Mohammad K Khan, Michael C Lowe, Haydn Kissick, Zachary S Buchwald, David C Qian
26 March 2024
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cellsMaxim Yankelevich, Archana Thakur, Shakeel Modak, Roland Chu, Jeffrey Taub, Alissa Martin, Dana Schalk, Amy Schienshang, Sarah Whitaker, Katie Rea, Daniel W Lee, Qin Liu, Anthony F Shields, Nai-Kong V Cheung, Lawrence G Lum
21 March 2024
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trialDirk Schadendorf, Jason John Luke, Paolo A Ascierto, Georgina V Long, Piotr Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz-Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S CarlinoSee the full list of authors
13 March 2024
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trialHeinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino, Mark Kochenderfer, Elena Elez, Spencer H Shao, Dustin Deming, Regan Holdridge, Timothy Larson, Eric Chen, Amit Mahipal, Antonio Ucar, Dana CullenSee the full list of authors
13 March 2024
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)Ju Won Kim, Hyo Jin Lee, Ji Yoon Lee, Sook Ryun Park, Yu Jung Kim, In Gyu Hwang, Woo Kyun Bae, Jae Ho Byun, Jung Sun Kim, Eun Joo Kang, Jeeyun Lee, Sang Joon Shin, Won Jin Chang, Eun-Ok Kim, Jason K SaSee the full list of authors
13 March 2024
Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancerArun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andrew Weisman, Beatriz Walter-Rodriguez, Rena Ito, Yulia Vugmeyster, Masashi SatoSee the full list of authors
13 March 2024
Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumorsQian Tao, Nian Liu, Jie Wu, Jing Chen, Xiang Chen, Cong Peng
11 March 2024
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinomaDanny Rischin, Brett G M Hughes, Nicole Basset-Séguin, Dirk Schadendorf, Samantha Bowyer, Sabiha Trabelsi Messai, Friedegund Meier, Thomas K Eigentler, Victoria Casado Echarren, Brian Stein, Marie Beylot-Barry, Sophie Dalac, Brigitte Dréno, Michael R Migden, Axel HauschildSee the full list of authors
11 March 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumorsNikhil I Khushalani, Patrick A Ott, Robert L Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason J Luke, Ignacio Melero, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti SanyalSee the full list of authors
7 March 2024